Trial | NCT02790164  Report issue

Title

Continuous NMB in PCAS
Continuous Neuromuscular Blocking Agent for out-of Hospital Cardiac Arrest; Multicenter Randomized Controlled Trial

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    81
The main purpose of this study is to test the hypothesis that continuous NMB could improve outcome in cardiac arrest patients treated with therapeutic hypothermia.
Study Started
May 31
2016
Primary Completion
Nov 30
2016
Last Update
Dec 07
2016
Estimate

Drug Esmeron

Neuromuscular Blockade

  • Other names: Rocuronium

Drug Saline

Normal Saline

Rocuronium Experimental

Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.

Usual Care Placebo Comparator

Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.

Criteria 

Inclusion Criteria:

Adult (older than 19)
OHCA with sustained ROSC
Comatose (i.e., not following commands) following ROSC
Undergoing targeted temperature management (TTM)
Time of enrollment ≤ 6hrs from ROSC

Exclusion Criteria:

Pre-existing dementia, brain injury, or dependence on others for ADLs (CPC > 3)
Traumatic etiology for cardiac arrest
Protected population (pregnant, prisoner)
No Results Posted